Clinical & Experimental Immunology · 2009 · 24 citations · 37 references
Veterinary MedicineImmunologyPharmacologyInflammationInnate ImmunitySepsisCytokine BiologyCytokine-mediated PathologyInflammation In Infectious DiseaseInflammatory SignalingSepsis PathophysiologySeptic ShockBacterial Cell Wall PhysiologyEndotoxin ToleranceEndotoxin-mediated InflammationImmunosuppression After SepsisProinflammatory MediatorsSepsis-associated Cytokine DysregulationSepsis-associated Cytokine ResponseSepsis-associated Inflammation
Gram-negative infections can result in endotoxic shock, which is the most common cause of death in intensive care units. Most of the undesirable effects in sepsis and septic shock have been ascribed to lipopolysaccharide (LPS), a normal constituent of the bacterial wall. The response to LPS involves rapid secretion of proinflammatory cytokines [tumour necrosis factor-alpha, interleukin (IL)-1, IL-6, IL-8, interferon-gamma] and the concomitant induction of anti-inflammatory mediators such as IL-10 and transforming growth factor-beta and glucocorticoids (GC), which render the host temporarily refractory to subsequent lethal doses of LPS challenge in a process known as LPS or endotoxin tolerance. Although protective from the development of sepsis or systemic inflammation, endotoxin tolerance has also been pointed out as the principal cause of the non-specific immunosuppression described in these patients. In this report we demonstrate, using a mouse model, that while the maintenance of tolerance is dependent upon GC, the establishment of tolerance by LPS could be inhibited by dexamethasone (Dex), a synthetic GC. Conversely, we demonstrated that mifepristone (RU486), a known GC receptor antagonist, was capable of inducing a transient and reversible disruption of endotoxin tolerance, also permitting partial restoration of the humoral immune response in LPS tolerant/immunosuppressed mice. These results are encouraging for the management of immunosuppression in sepsis and/or non-infectious shock, and deserve further investigation in the future.
37
Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
Wolf‐Dietrich Döcke, Felix Randow, Uta Syrbe et al. · Nature Medicine · 1997 · 1.2K citations
Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor
Alice M. Wang, Abla A. Creasey, Martha Ladner et al. · Science · 1985 · 631 citations
Christian Meisel, Joerg C. Schefold, René Pschowski et al. · American Journal of Respiratory and Critical Care Medicine · 2009 · 626 citations
Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients
Ajit P. Limaye, Katharine A. Kirby, Gordon D. Rubenfeld et al. · JAMA · 2008 · 577 citations · Full text
The sepsis seesaw: tilting toward immunosuppression
Richard S. Hotchkiss, Craig M. Coopersmith, Jonathan E. McDunn et al. · Nature Medicine · 2009 · 566 citations · Full text